In addition, given the complexity and immunosuppressive properties of the solid tumor microenvironment, combination with other therapies, such as immune checkpoint inhibitors (i.e., CTLA-4 and PD-1 antibodies), may offer better efficacy to eliminate cancer and its recurrence. This evidence concerns the gene CTLA4 and cancer.